⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SLXN News
Silexion Therapeutics Corp Ordinary Shares
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
globenewswire.com
SLXN
Form 8-K
sec.gov
SLXN
SLXNW
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
globenewswire.com
SLXN
Form 8-K
sec.gov
SLXN
SLXNW
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
globenewswire.com
SLXN
Form 8-K
sec.gov
SLXN
SLXNW
Form 8-K
sec.gov
SLXN
SLXNW
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer
globenewswire.com
SLXN
Form 8-K
sec.gov
SLXN
SLXNW
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
globenewswire.com
SLXN